An Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With GLP-1 Receptor Agonists
Phase of Trial: Phase IV
Latest Information Update: 21 Jul 2017
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 21 Jul 2017 Last checked against ClinicalTrials.gov.record.
- 10 Jun 2017 Biomarkers information updated
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.